# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
iBio (AMEX:IBIO) reported quarterly losses of $(0.71) per share. This is a 92.55 percent increase over losses of $(9.53) per sh...
-SEC Filing
iBio surged after collaborating with AstralBio Inc. to develop antibodies for obesity & cardiometabolic conditions. Shares ...
IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for ob...
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agre...
iBio, Inc. an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities...
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.